AdAlta Secures AU$2.5 Million to Progress BZDS1901 CAR-T Therapy.
AdAlta Limited (ASX: 1AD) has raised AU$2.5 million through a private placement to support the advancement of its lead CAR-T therapy, BZDS1901, aimed at treating advanced mesothelioma. The funding will be directed toward achieving key regulatory milestones, including engagement with the US FDA for pre-IND guidance, and establishing local manufacturing capabilities in Australia. The capital raise reflects strong investor confidence, driven by promising clinical outcomes where the therapy showed meaningful tumour reduction, including complete remission in certain patients and prolonged survival without recurrence. Notably, these results were observed in individuals who had limited success with prior treatments such as chemotherapy and immunotherapy. The company also continues to develop its “East to West” strategy, combining Asian research efficiency with Western regulatory and commercialization pathways. Overall, the funding strengthens AdAlta’s ability to progress clinical development and expand its presence in the growing immunotherapy space.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
AdAlta Secures AU$2.5 Million to Progress BZDS1901 CAR-T Therapy.
AdAlta Limited (ASX: 1AD) has raised AU$2.5 million through a private placement to support the advancement of its lead CAR-T therapy, BZDS1901, aimed at treating advanced mesothelioma. The funding will be directed toward achieving key regulatory milestones, including engagement with the US FDA for pre-IND guidance, and establishing local manufacturing capabilities in Australia. The capital raise reflects strong investor confidence, driven by promising clinical outcomes where the therapy showed meaningful tumour reduction, including complete remission in certain patients and prolonged survival without recurrence. Notably, these results were observed in individuals who had limited success with prior treatments such as chemotherapy and immunotherapy. The company also continues to develop its “East to West” strategy, combining Asian research efficiency with Western regulatory and commercialization pathways. Overall, the funding strengthens AdAlta’s ability to progress clinical development and expand its presence in the growing immunotherapy space.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au